The coming of age story of RNAi technology
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development.…
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development.…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and…
The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with…
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal…
Although biotech may seem like an industry that has only just gotten started, it was…
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA?…
Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using…